External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma

References

• Klastersky J, Paesmans M. Risk-adapted strategy for the management of febrile neutropenia in cancer patients. Support Care Cancer 2007;15:477–482.
   PubMed Web of Science ®Google Scholar
• Schwenkglenks M, Jackisch C, Constenla M, et al. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 2006;14:901–909.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258–2266.
   PubMed Web of Science ®Google Scholar
• Lathia N, Mittmann N, DeAngelis C, et al. Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 2010;116:742–748.
   PubMed Web of Science ®Google Scholar
• Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med 2011;2:859–866.
   PubMed Web of Science ®Google Scholar
• Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012;380:848–857.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008;16:1299–1309.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte colony-stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8–32.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24: 3187–3205.
   PubMed Web of Science ®Google Scholar
• Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 2010;21(Suppl. 5):v248–v251.
   PubMed Web of Science ®Google Scholar
• Crawford J, Allen J, Armitage J, et al. Myeloid growth factors. J Natl Compr Canc Netw 2011;9:914–932.
   PubMed Web of Science ®Google Scholar
• Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2013;31:794–810.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427–437.
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Rayson D, Vincent M, et al. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. Am J Clin Oncol 2008;31:369–374.
   PubMed Web of Science ®Google Scholar
• Chen C, Chan A, Yap K. Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy. J Oncol Pharm Pract 2012 Sep 25. [Epub ahead of print]
   Google Scholar
• Pettengell R, Bosly A, Szucs TD, et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol 2009;144:677–685.
   PubMed Web of Science ®Google Scholar
• Altman DG, Royston P. What do we mean by validating a prognostic model?. Stat Med 2000;19:453–473.
   PubMed Web of Science ®Google Scholar
• Collins GS, Moons KG. Comparing risk prediction models. BMJ 2012;344:e3186.
   PubMed Web of Science ®Google Scholar
• Hosmer W, Malin J, Wong M. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer 2011;19:333–341.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Kuderer NM, Crawford J, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011;117:1917–1927.
   PubMed Web of Science ®Google Scholar
• Jenkins P, Scaife J, Freeman S. Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer. Ann Oncol 2011;23: 1766–1771.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Schwenkglenks M, Leonard R, et al. Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. Support Care Cancer 2011;19:483–490.
   PubMed Web of Science ®Google Scholar
• Salar A, Haioun C, Rossi FG, et al. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. Leuk Res 2012;36:548–553.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Johnson HE, Lugtenburg PJ, et al. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer 2012;20:647–652.
   PubMed Web of Science ®Google Scholar
• Bleeker SE, Moll HA, Steyerberg EW, et al. External validation is necessary in prediction research: a clinical example. J Clin Epidemiol 2003;56:826–832.
   PubMed Web of Science ®Google Scholar
• Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999;130:515–524.
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Bleeker SE, Moll HA, et al. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol 2003;56:441–447.
   PubMed Web of Science ®Google Scholar
• Altman DG, Vergouwe Y, Royston P, et al. Prognosis and prognostic research: validating a prognostic model. BMJ 2009;338:b605.
   PubMed Web of Science ®Google Scholar
• López-Pousa A, Rifà J, Casas de Tejerina A, et al. Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours. Eur J Cancer Care 2010;19:648–655.
   PubMed Web of Science ®Google Scholar
• Datema FR, Ferrier MB,Vergouwe Y, et al. Update and external validation of a head and neck cancer prognostic model. Head Neck 2012 Jul 30. [Epub ahead of print]
   Web of Science ®Google Scholar
• Mallett S, Royston P, Dutton S, et al. Reporting methods in studies developing prognostic models in cancer: a review. BMC Med 2010;8:20.
   PubMed Web of Science ®Google Scholar
• Moons KG, Kengne AP, Grobbee E, et al. Risk prediction models: II. External validation, model updating, and impact assessment. Heart 2012;98:691–698.
   PubMed Web of Science ®Google Scholar